reverse-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
=== Skinny Revolution === Pickston founded Skinny Revolution to help people to lose weight after she gained 7 stone in 14 months, partly whilst pregnant, using a Wegovy (semaglutide) injection, which is a 2.4 mg injectable prescription medicine used as an appetite suppressant.
=== Category:EC 6.2 (form carbon–sulfur bonds) === EC 6.2.1.1: Acetate—CoA ligase EC 6.2.1.2: Medium-chain acyl—CoA ligase EC 6.2.1.3: Long-chain-fatty-acid—CoA ligase EC 6.2.1.4: Succinate—CoA ligase (GDP-forming) EC 6.2.1.5: Succinate—CoA ligase (ADP-forming) EC 6.2.1.6: Glutarate—CoA ligase EC 6.2.1.7: Cholate—CoA ligase EC 6.2.1.8: Oxalate—CoA ligase EC 6.2.1.9: Malate—CoA ligase EC 6.2.1.10: Acid—CoA ligase (GDP-forming) EC 6.2.1.11: Biotin—CoA ligase EC 6.2.1.12: 4-Coumarate—CoA ligase EC 6.2.1.13: Acetate—CoA ligase (ADP-forming) EC 6.2.1.14: 6-carboxyhexanoate—CoA ligase EC 6.2.1.15: Arachidonate—CoA ligase EC 6.2.1.16: Acetoacetate—CoA ligase EC 6.2.1.17: Propionate—CoA ligase EC 6.2.1.18: Citrate—CoA ligase EC 6.2.1.19: Long-chain-fatty-acid-luciferin-component ligase EC 6.2.1.20: Long-chain-fatty-acid-(acyl-carrier-protein) ligase EC 6.2.1.21: Transferred entry: 6.2.1.30 EC 6.2.1.22: (citrate (pro-3S)-lyase) ligase EC 6.2.1.23: Dicarboxylate—CoA ligase EC 6.2.1.24: Phytanate—CoA ligase EC 6.2.1.25: Benzoate—CoA ligase EC 6.2.1.26: o-Succinylbenzoate—CoA ligase EC 6.2.1.27: 4-hydroxybenzoate—CoA ligase EC 6.2.1.28: 3-alpha,7-alpha-dihydroxy-5-beta-cholestanate—CoA ligase EC 6.2.1.29: Transferred entry: 6.2.1.7 EC 6.2.1.30: Phenylacetate—CoA ligase EC 6.2.1.31: 2-furoate—CoA ligase EC 6.2.1.32: Anthranilate—CoA ligase EC 6.2.1.33: 4-chlorobenzoate—CoA ligase EC 6.2.1.34: trans-Feruloyl—CoA synthase EC 6.2.1.35: ACP-SH:acetate ligase EC 6.2.1.36: 3-hydroxypropionyl-CoA synthase EC 6.2.1.37: 3-hydroxybenzoate—CoA ligase EC 6.2.1.38: (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA synthase EC 6.2.1.39: (butirosin acyl-carrier protein)—L-glutamate ligase EC 6.2.1.40: 4-Hydroxybutyrate—CoA ligase EC 6.2.1.41: 3-((3aS,4S,7aS)-7a-methyl-1,5-dioxo-octahydro-1H-inden-4-yl)propanoate—CoA ligase EC 6.2.1.42: 3-oxocholest-4-en-26-oate—CoA ligase EC 6.2.1.43: 2-hydroxy-7-methoxy-5-methyl-1-naphthoate—CoA ligase EC 6.2.1.44: 3-(methylthio)propionyl—CoA ligase EC 6.2.1.45: E1 ubiquitin-activating enzyme EC 6.2.1.46: L-allo-Isoleucine—holo-CmaA peptidyl-carrier protein ligase EC 6.2.1.47: Medium-chain-fatty-acid-(acyl-carrier-protein) ligase EC 6.2.1.48: Carnitine—CoA ligase EC 6.2.1.49: Long-chain fatty acid adenylyltransferase FadD28 EC 6.2.1.50: 4-hydroxybenzoate adenylyltransferase FadD22 EC 6.2.1.51: 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 6.2.1.52: L-Firefly luciferin—CoA ligase EC 6.2.1.53: L-Proline—L-prolyl-carrier protein ligase EC 6.2.1.54: D-Alanine—D-alanyl-carrier protein ligase EC 6.2.1.55: E1 SAMP-activating enzyme
== Clinical significance == As bacteria are the responsible pathogen for many infections and illnesses, the biochemical and structural components that distinguish disease causing bacterial cells from native eukaryotic cells are of great interest from a clinical perspective. Gram-negative bacteria tend to be more antimicrobial resistant than gram-positive bacteria, and also possess a much more significant periplasmic space between their two membrane bilayers. Since eukaryotes do not possess a periplasmic space, structures and enzymes found in the gram-negative periplasm are attractive targets for antimicrobial drug therapies. Additionally, vital functions such as facilitation of protein folding, protein transport, cell signaling, structural integrity, and nutrient uptake are performed by periplasm components, making it rich in potential drug targets. Aside from enzymes and structural components that are vital to cell function and survival, the periplasm also contains virulence-associated proteins such as DsbA that can be targeted by antimicrobial therapies. Due to their role in catalyzing disulfide bond formation for a variety of virulence factors, the DsbA/DsbB system has been of particular interest as a target for anti-virulence drugs. The periplasmic space is deeply interconnected with the pathogenesis of disease in the setting of microbial infection. Many of the virulence factors associated with bacterial pathogenicity are secretion proteins, which are often subject to post-translational modification including disulfide bond formation.
Respiration involves drawing water into the mantle cavity through an aperture, passing it through the gills, and expelling it through the siphon. Ingress is achieved by contraction of radial muscles in the mantle wall, and flapper valves shut when strong, circular muscles expel the water through the siphon. Extensive connective tissue lattices support the respiratory muscles and allow them to inflate the respiratory chamber. The lamella structure of the gills allows for high oxygen uptake, up to 65% in water at 20 °C (68 °F). Respiration can also play a role in locomotion, as an octopus can propel its body shooting water out of the siphon. The thin skin absorbs additional oxygen. When resting, around 41% of oxygen absorption is through the skin, reduced to 33% when the octopus swims, despite the amount of oxygen absorption increasing as water flows over the body. When it is resting after a meal, skin absorption can drop to 3%.
Sources: en.wikipedia.org
When a semen analysis does indicate abnormal results, lifestyle factors recommendations prior to a new semen sample include a nutritional diet, as well as limitations on smoking and alcohol use. A cold bath and removal of tight-fitted underwear apparel may also be recommended within the month prior to re-examination.
Hundreds of additional cases of liver complications in people taking bicalutamide exist in the FDA Adverse Event Reporting System (FAERS) database. In all of the published case reports of liver toxicity with bicalutamide, the onset of symptoms was within the first 6 months of treatment. Symptoms that may indicate liver dysfunction include nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, dark urine, and jaundice. There are also published case reports of interstitial pneumonitis and eosinophilic lung disease associated with bicalutamide. along with hundreds of additional instances in the FAERS database as well. Interstitial pneumonitis can potentially progress to pulmonary fibrosis and may be fatal. Symptoms that may indicate lung dysfunction include dyspnea (difficult breathing or shortness of breath), cough, and pharyngitis (inflammation of the pharynx, resulting in sore throat). The exact incidence of liver toxicity and interstitial pneumonitis with bicalutamide are unknown, but both are said to be very rare events. A few cases of photosensitivity have been reported with bicalutamide. Hypersensitivity reactions (drug allergy) like angioedema and hives have also uncommonly been reported in association with bicalutamide. Because it is an antiandrogen, bicalutamide has a theoretical risk of birth defects like ambiguous genitalia in male fetuses. Due to its teratogenic capacity, contraception should be used in women taking bicalutamide who are fertile and sexually active.
Two days into his term, Noboa ordered the Ministry of the Interior to repeal the Drug Consumption Table, which he said encouraged "micro-trafficking". He simultaneously instructed the Interior and Health Ministries to create programs to reduce the consumption of narcotics and provide treatment for drug abusers.
The University of Pittsburgh Medical Center (UPMC) is an American integrated global nonprofit health enterprise that has 100,000 employees, 40 hospitals with more than 8,000 licensed beds, 800 clinical locations including outpatient sites and doctors' offices, a 3.8 million-member health insurance division, as well as commercial and international ventures. It is closely affiliated with its academic partner, the University of Pittsburgh. It is considered a leading American health care provider, as its flagship facilities have ranked in U.S. News & World Report "Honor Roll" of the approximately 15 to 20 best hospitals in the U.S. for over 15 years. As of 2016, its flagship hospital UPMC Presbyterian was ranked 12th nationally among the best hospitals (and first in Pennsylvania) by U.S. News & World Report and ranked in 15 of 16 specialty areas when including UPMC Magee-Womens Hospital. This does not include UPMC Children's Hospital of Pittsburgh which ranked in the top 10 of pediatric centers in a separate US News ranking.
== Industrial applications == Although the use of protecting groups is not preferred in industrial syntheses, they are still used in industrial contexts, e.g. sucralose (sweetener) or the Roche synthesis of oseltamivir (Tamiflu, an antiviral drug) An important example of industrial applications of protecting group theory is the synthesis of ascorbic acid (Vitamin C) à la Reichstein.
Sources: en.wikipedia.org
=== Degradation === Glycine is degraded via three pathways. The predominant pathway in animals and plants is the reverse of the glycine synthase pathway mentioned above. In this context, the enzyme system involved is usually called the glycine cleavage system:
The tunica externa (Neo-Latin "outer coat"), also known as the tunica adventitia (Neo-Latin "additional coat"), is the outermost tunica (layer) of a blood vessel, surrounding the tunica media. It is mainly composed of collagen and, in arteries, is supported by external elastic lamina. The collagen serves to anchor the blood vessel to nearby organs, giving it stability. The three layers of the blood vessels are: an inner tunica intima, a middle tunica media, and an outer tunica externa.
204Pb(48Ca,xn)252−xNo (x=2,3) The measurement of the 2n excitation function for this reaction was reported in 2001 by Yuri Oganessian at the FLNR. They reported a new isotope 250No with a half-life of 36 μs. The reaction was used in 2003 to study the spectroscopy of 250No.They were able to observe two spontaneous fission activities with half-lives of 5.6 μs and 54 μs and assigned to 250No and 249No, respectively. The latter activity was later assigned to a K-isomer in 250No. The reaction was reported in 2006 by Peterson et al. at the Argonne National Laboratory (ANL) in a study of SF in 250No. They detected two activities with half-lives of 3.7 μs and 43 μs and both assigned to 250No, the latter associated with a K-isomer. In 2020, a team at FLNR repeated this reaction and found a new 9.1-MeV alpha particle activity correlated to 245Fm and 241Cf, which they assigned to the new isotope 249No.
Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-based COVID-19 vaccine. It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. It was developed under the name ARCT-154, also known as VBC-COV19-154 in Vietnam, by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing. Zapomeran was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved. Zapomeran was authorized for medical use in the European Union in February 2025, and in the UK in January 2026.
=== Healthcare assistants/medicines counter assistants === In the UK, this group of staff can sell certain medicines (including pharmacy only and general sales list medicines) over the counter. They cannot prepare prescription-only medicines for supply to patients.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.